Previsión

El precio objetivo medio de los analistas es de +22,32€ (+44,28%). La mediana es de +22,32€ (+44,28%).

Comprar	9
Mantener	5
Vender	1

Noticias Ir al feed de noticias

NovoCure shows revenue growth but remains cash-flow negative as it expands TTFields devices

NovoCure’s Tumor Treating Fields devices, including Optune Gio and newly FDA-approved Optune Pax, drove revenue growth to about $655–704 million range, but the company posted a net loss (≈$136.2 million in FY2025) and negative free cash flow (−$75.7 million) as it invests in expansion. Debt and a near 0.9x debt-to-equity ratio, reliance on single-source suppliers, and expected negative free cash flow through 2027 pressure financing needs. Valuation looks more attractive than peer Omeros, but NovoCure faces execution and reimbursement risks that could limit near-term shareholder returns. » Más en finance.yahoo.com
Novocure shares fall after TRIDENT phase‑3 study – primary endpoint missed

The TRIDENT phase‑3 trial by Novocure did not meet its primary endpoint in newly diagnosed glioblastoma: median overall survival 17.7 vs. 17.5 months (hazard ratio 0.953; p=0.519) in 981 patients. The result prevents a potential expansion of Optune Gio use into the earlier radiochemotherapy phase, which had been seen as an important growth driver. Consequently, the stock plunged in pre‑market trading, exacerbated by a risk‑averse market environment after signals from the Fed. » Más en de.investing.com
NovoCure CEO sells 34,273 shares for about $615,000

Frank Leonard, CEO of NovoCure, reported an open-market sale of 34,273 common shares on June 4, 2026, for roughly $615,000. The sale reduced his direct holdings from 493,793 to 459,520 shares, representing 6.94% of his prior direct stake, and is his largest individual open-market sale to date. No indirect or derivative interests were affected; post-transaction direct holdings were valued at about $8.3 million. » Más en finance.yahoo.com

Datos financieros de la empresa

En el último trimestre, NovoCure tuvo unos ingresos de 160,86 Mio€ y un beneficio neto de −13,72 Mio€

(EUR)	jun 2026	YoY
Ingresos	+160,86 Mio	19,39%
Beneficio bruto	+124,84 Mio	25,41%
Beneficio neto	−13,72 Mio	59,71%
EBITDA	−9,25 Mio	65,41%

Datos fundamentales

Métrica	Valor
Capitalización bursátil	+1,79 Mrd€
Número de acciones	116,45 Mio
Máximo/mínimo de 52 semanas	+18,41€ - +8,43€
Dividendos	No
Beta	0,98
Ratio P/E	−13,76
Ratio PEG	−4,34
Ratio P/B	+6,14
Ratio P/S	+2,98

Perfil de la empresa

NovoCure Limited, ein Onkologieunternehmen, beschäftigt sich mit der Entwicklung, Herstellung und Vermarktung von Geräten zur Behandlung von Tumorfeldern (TTFields) für die Behandlung von soliden Tumoren in den Vereinigten Staaten, Europa, dem Nahen Osten, Afrika, Japan und Großchina. Zu seinen TTFields-Geräten gehören Optune für die Behandlung von Glioblastomen und Optune Lua für die Behandlung von malignen Pleuramesotheliomen. Das Unternehmen hat außerdem laufende oder abgeschlossene klinische Studien zur Untersuchung von TTFields bei Hirnmetastasen, Magenkrebs, Glioblastom, Leberkrebs, nicht-kleinzelligem Lungenkrebs, Bauchspeicheldrüsenkrebs und Eierstockkrebs. NovoCure Limited wurde im Jahr 2000 gegründet und hat seinen Hauptsitz in Saint Helier, Jersey.